Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

2.340 +0.190 (+8.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,895,741
Open 2.200
Bid (Size) 2.340 (282)
Ask (Size) 2.350 (54)
Prev. Close 2.150
Today's Range 2.195 - 2.410
52wk Range 1.460 - 3.260
Shares Outstanding 66,497,370
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xeris Biopharma Announces CEO Succession Plan
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire

Performance

YTD
+3.31%
+3.31%
1 Month
+0.86%
+0.86%
3 Month
+18.18%
+18.18%
6 Month
-16.43%
-16.43%
1 Year
-3.31%
-3.31%

More News

Read More
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
Via ACCESSWIRE
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Why Are Xeris Biopharma Shares Moving Monday?
Via Benzinga
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For March 6, 2024
Via Benzinga
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down
Via InvestorPlace
Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.